Autoimmunity in Retinitis Pigmentosa

Semmelweis University

Status: Unknown

Conditions: Retinitis Pigmentosa

Treatments: Drug: twice-daily dosage with 0.5% cyclosporine-A eyedrops

Study type: Interventional

Funder types: Other

Identifiers

NCT00433277

KMolnar

Details and patient eligibility

About

Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of retinitis pigmentosa

Exclusion criteria

• Cataract
• Extremely low ERG wave amplitude (less than 8% of normal)